Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

A deeper look at skin scoring in scleroderma - surrogate, outcome, neither or both?

Seibold JR.

Rheumatology (Oxford). 2019 Oct 5. pii: kez432. doi: 10.1093/rheumatology/kez432. [Epub ahead of print] No abstract available.

PMID:
31586429
2.

Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.

Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, Castina S, Griffith LM, Goldstein JS, Wallace D, Craciunescu O, Khanna D, Folz RJ, Goldin J, St Clair EW, Seibold JR, Phillips K, Mineishi S, Simms RW, Ballen K, Wener MH, Georges GE, Heimfeld S, Hosing C, Forman S, Kafaja S, Silver RM, Griffing L, Storek J, LeClercq S, Brasington R, Csuka ME, Bredeson C, Keever-Taylor C, Domsic RT, Kahaleh MB, Medsger T, Furst DE; SCOT Study Investigators.

N Engl J Med. 2018 Jan 4;378(1):35-47.

3.

Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort.

Mihai C, Antic M, Dobrota R, Bonderman D, Chadha-Boreham H, Coghlan JG, Denton CP, Doelberg M, Grünig E, Khanna D, McLaughlin VV, Müller-Ladner U, Pope JE, Rosenberg DM, Seibold JR, Vonk MC, Distler O.

Ann Rheum Dis. 2018 Jan;77(1):128-132. doi: 10.1136/annrheumdis-2017-211480. Epub 2017 Oct 23.

PMID:
29061853
4.

Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials.

Humbert M, Singh M, Furst DE, Khanna D, Seibold JR.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v33-v37. doi: 10.1093/rheumatology/kex197. Review.

5.

Editorial: Clinical Trials in Raynaud's Phenomenon: A Spoonful of Sugar (Pill) Makes the Medicine Go Down (in Flames).

Seibold JR, Wigley FM.

Arthritis Rheumatol. 2017 Dec;69(12):2256-2258. doi: 10.1002/art.40307. Epub 2017 Nov 10. No abstract available.

6.

Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis.

Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, Distler O, Foeldvari I, Kuwana M, Matucci-Cerinic M, Mayes M, Medsger T Jr, Merkel PA, Pope JE, Seibold JR, Steen V, Stevens W, Denton CP.

J Scleroderma Relat Disord. 2017 Jan-Apr;2(1):11-18. doi: 10.5301/jsrd.5000231.

7.

An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial.

Khanna D, Albera C, Fischer A, Khalidi N, Raghu G, Chung L, Chen D, Schiopu E, Tagliaferri M, Seibold JR, Gorina E.

J Rheumatol. 2016 Sep;43(9):1672-9. doi: 10.3899/jrheum.151322. Epub 2016 Jul 1.

8.

The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.

Khanna D, Berrocal VJ, Giannini EH, Seibold JR, Merkel PA, Mayes MD, Baron M, Clements PJ, Steen V, Assassi S, Schiopu E, Phillips K, Simms RW, Allanore Y, Denton CP, Distler O, Johnson SR, Matucci-Cerinic M, Pope JE, Proudman SM, Siegel J, Wong WK, Wells AU, Furst DE.

Arthritis Rheumatol. 2016 Feb;68(2):299-311. doi: 10.1002/art.39501.

9.

The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.

Khanna D, Berrocal VJ, Giannini EH, Seibold JR, Merkel PA, Mayes MD, Baron M, Clements PJ, Steen V, Assassi S, Schiopu E, Phillips K, Simms RW, Allanore Y, Denton CP, Distler O, Johnson SR, Matucci-Cerinic M, Pope JE, Proudman SM, Siegel J, Wong WK, Wells AU, Furst DE.

Arthritis Care Res (Hoboken). 2016 Feb;68(2):167-78. doi: 10.1002/acr.22804.

10.

Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group.

Khanna D, Mittoo S, Aggarwal R, Proudman SM, Dalbeth N, Matteson EL, Brown K, Flaherty K, Wells AU, Seibold JR, Strand V.

J Rheumatol. 2015 Nov;42(11):2168-71. doi: 10.3899/jrheum.141182. Epub 2015 Mar 1. Review.

11.

Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis.

Wallace B, Kafaja S, Furst DE, Berrocal VJ, Merkel PA, Seibold JR, Mayes MD, Khanna D.

Rheumatology (Oxford). 2015 Aug;54(8):1369-79. doi: 10.1093/rheumatology/keu456. Epub 2015 Feb 9.

12.

Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study.

Visovatti SH, Distler O, Coghlan JG, Denton CP, Grünig E, Bonderman D, Müller-Ladner U, Pope JE, Vonk MC, Seibold JR, Torres-Martin JV, Doelberg M, Chadha-Boreham H, Rosenberg DM, McLaughlin VV, Khanna D.

Arthritis Res Ther. 2014 Dec 10;16(6):493. doi: 10.1186/s13075-014-0493-1.

13.

Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards.

Khanna D, Furst DE, Allanore Y, Bae S, Bodukam V, Clements PJ, Cutolo M, Czirjak L, Denton CP, Distler O, Walker UA, Matucci-Cerinic M, Müller-Ladner U, Seibold JR, Singh M, Tyndall A.

Rheumatology (Oxford). 2015 Jan;54(1):144-51. doi: 10.1093/rheumatology/keu288. Epub 2014 Aug 13. Review.

14.

Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria.

Johnson SR, Naden RP, Fransen J, van den Hoogen F, Pope JE, Baron M, Tyndall A, Matucci-Cerinic M, Denton CP, Distler O, Gabrielli A, van Laar JM, Mayes M, Steen V, Seibold JR, Clements P, Medsger TA Jr, Carreira PE, Riemekasten G, Chung L, Fessler BJ, Merkel PA, Silver R, Varga J, Allanore Y, Mueller-Ladner U, Vonk MC, Walker UA, Cappelli S, Khanna D.

J Clin Epidemiol. 2014 Jun;67(6):706-14. doi: 10.1016/j.jclinepi.2013.12.009. Epub 2014 Apr 8.

15.

Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis.

Wiese AB, Berrocal VJ, Furst DE, Seibold JR, Merkel PA, Mayes MD, Khanna D.

Arthritis Care Res (Hoboken). 2014 Nov;66(11):1731-9. doi: 10.1002/acr.22339.

16.

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials.

Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankel S, Oddis CV, Denton CP, Fischer A, Kowal-Bielecka OM, LeSage D, Merkel PA, Phillips K, Pittrow D, Swigris J, Antoniou K, Baughman RP, Castelino FV, Christmann RB, Christopher-Stine L, Collard HR, Cottin V, Danoff S, Highland KB, Hummers L, Shah AA, Kim DS, Lynch DA, Miller FW, Proudman SM, Richeldi L, Ryu JH, Sandorfi N, Sarver C, Wells AU, Strand V, Matteson EL, Brown KK, Seibold JR; CTD-ILD Special Interest Group.

Thorax. 2014 May;69(5):428-36. doi: 10.1136/thoraxjnl-2013-204202. Epub 2013 Dec 24. Erratum in: Thorax. 2014 Sep;69(9):834. CTD-ILD Special Interest Group [added]; multiple investigator names added.

17.

Recognition of pulmonary hypertension in the rheumatology community: lessons from a Quality Enhancement Research Initiative.

Khanna D, Tan M, Furst DE, Hill NS, McLaughlin VV, Silver RM, Steen VD, Langer A, Seibold JR; QuERI-SSc Investigators.

Clin Exp Rheumatol. 2014 Nov-Dec;32(6 Suppl 86):S-21-7. Epub 2013 Dec 2.

PMID:
24295227
18.

2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Müller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE.

Arthritis Rheum. 2013 Nov;65(11):2737-47. doi: 10.1002/art.38098. Epub 2013 Oct 3.

19.

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative.

van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Müller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Ellen Csuka M, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE.

Ann Rheum Dis. 2013 Nov;72(11):1747-55. doi: 10.1136/annrheumdis-2013-204424.

PMID:
24092682
20.

Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era.

Rubenfire M, Huffman MD, Krishnan S, Seibold JR, Schiopu E, McLaughlin VV.

Chest. 2013 Oct;144(4):1282-1290. doi: 10.1378/chest.12-0653.

PMID:
23744060
21.

Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.

Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D, Müller-Ladner U, Pope JE, Vonk MC, Doelberg M, Chadha-Boreham H, Heinzl H, Rosenberg DM, McLaughlin VV, Seibold JR; DETECT study group.

Ann Rheum Dis. 2014 Jul;73(7):1340-9. doi: 10.1136/annrheumdis-2013-203301. Epub 2013 May 18.

22.

Open label study of escalating doses of oral treprostinil diethanolamine in patients with systemic sclerosis and digital ischemia: pharmacokinetics and correlation with digital perfusion.

Shah AA, Schiopu E, Hummers LK, Wade M, Phillips K, Anderson C, Wise R, Boin F, Seibold JR, Wigley F, Rollins KD.

Arthritis Res Ther. 2013 Apr 18;15(2):R54. doi: 10.1186/ar4216.

23.

Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial.

Hung EW, Mayes MD, Sharif R, Assassi S, Machicao VI, Hosing C, St Clair EW, Furst DE, Khanna D, Forman S, Mineishi S, Phillips K, Seibold JR, Bredeson C, Csuka ME, Nash RA, Wener MH, Simms R, Ballen K, Leclercq S, Storek J, Goldmuntz E, Welch B, Keyes-Elstein L, Castina S, Crofford LJ, Mcsweeney P, Sullivan KM.

J Rheumatol. 2013 Apr;40(4):455-60. doi: 10.3899/jrheum.121087. Epub 2013 Feb 15.

24.

Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.

Merkel PA, Silliman NP, Clements PJ, Denton CP, Furst DE, Mayes MD, Pope JE, Polisson RP, Streisand JB, Seibold JR; Scleroderma Clinical Trials Consortium.

Arthritis Rheum. 2012 Oct;64(10):3420-9. doi: 10.1002/art.34427.

25.

Effect of oxidative stress on protein tyrosine phosphatase 1B in scleroderma dermal fibroblasts.

Tsou PS, Talia NN, Pinney AJ, Kendzicky A, Piera-Velazquez S, Jimenez SA, Seibold JR, Phillips K, Koch AE.

Arthritis Rheum. 2012 Jun;64(6):1978-89. doi: 10.1002/art.34336. Epub 2011 Dec 12.

26.

Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise.

Fransen J, Johnson SR, van den Hoogen F, Baron M, Allanore Y, Carreira PE, Czirják L, Denton CP, Distler O, Furst DE, Gabrielli A, Herrick A, Inanc M, Kahaleh B, Kowal-Bielecka O, Medsger TA Jr, Mueller-Ladner U, Riemekasten G, Sierakowski S, Valentini G, Veale D, Vonk MC, Walker U, Chung L, Clements PJ, Collier DH, Csuka ME, Jimenez S, Merkel PA, Seibold JR, Silver R, Steen V, Tyndall A, Matucci-Cerinic M, Pope JE, Khanna D.

Arthritis Care Res (Hoboken). 2012 Mar;64(3):351-7. doi: 10.1002/acr.20679.

27.

Analysis of the validation status of quality of life and functional disability measures in pulmonary arterial hypertension related to systemic sclerosis: results of a systematic literature analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).

Kowal-Bielecka O, Avouac J, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE, Distler O; Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis.

J Rheumatol. 2011 Nov;38(11):2419-27. doi: 10.3899/jrheum.110344. Epub 2011 Oct 1. Review.

PMID:
21965635
28.

Developing disease activity and response criteria in connective tissue disease-related interstitial lung disease.

Saketkoo LA, Matteson EL, Brown KK, Seibold JR, Strand V; Connective Tissue Disease-related Interstitial Lung Disease Special Interest Group.

J Rheumatol. 2011 Jul;38(7):1514-8. doi: 10.3899/jrheum.110281.

PMID:
21724725
29.

Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.

Khanna D, Furst DE, Maranian P, Seibold JR, Impens A, Mayes MD, Clements PJ, Getzug T, Hays RD.

J Rheumatol. 2011 Sep;38(9):1920-4. doi: 10.3899/jrheum.110225. Epub 2011 Jul 1.

30.

Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed.

Denton CP, Avouac J, Behrens F, Furst DE, Foeldvari I, Humbert M, Huscher D, Kowal-Bielecka O, Matucci-Cerinic M, Nash P, Opitz CF, Pittrow D, Rubin LJ, Seibold JR, Distler O.

Arthritis Res Ther. 2011 Jun 20;13(3):114. doi: 10.1186/ar3346.

31.

Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group.

Khanna D, Tseng CH, Farmani N, Steen V, Furst DE, Clements PJ, Roth MD, Goldin J, Elashoff R, Seibold JR, Saggar R, Tashkin DP.

Arthritis Rheum. 2011 Oct;63(10):3078-85. doi: 10.1002/art.30467.

32.

Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis.

Sharif R, Fritzler MJ, Mayes MD, Gonzalez EB, McNearney TA, Draeger H, Baron M; Canadian Scleroderma Research Group, Furst DE, Khanna DK, del Junco DJ, Molitor JA, Schiopu E, Phillips K, Seibold JR, Silver RM, Simms RW; GENISOS Study Group, Perry M, Rojo C, Charles J, Zhou X, Agarwal SK, Reveille JD, Assassi S, Arnett FC.

J Rheumatol. 2011 Aug;38(8):1622-30. doi: 10.3899/jrheum.110071. Epub 2011 May 15.

33.

Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis.

Rabquer BJ, Tsou PS, Hou Y, Thirunavukkarasu E, Haines GK 3rd, Impens AJ, Phillips K, Kahaleh B, Seibold JR, Koch AE.

Arthritis Res Ther. 2011 Feb 8;13(1):R18. doi: 10.1186/ar3242.

34.

Differences in presentation of younger and older systemic sclerosis patients in clinical trials.

Weng HH, Ranganath VK, Oh M, Park GS, Khanna D, Clements PJ, Seibold JR, Elashoff DA, Furst DE.

Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 62):S10-4. Epub 2010 Nov 3.

35.

Vascular alterations and sexual function in systemic sclerosis.

Impens AJ, Seibold JR.

Int J Rheumatol. 2010;2010:139020. doi: 10.1155/2010/139020. Epub 2010 Aug 5.

36.

Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis.

Bodukam V, Hays RD, Maranian P, Furst DE, Seibold JR, Impens A, Mayes MD, Clements PJ, Khanna D.

Rheumatology (Oxford). 2011 Feb;50(2):330-4. doi: 10.1093/rheumatology/keq296. Epub 2010 Sep 30.

37.

Discordance between patient and physician assessments of disease severity in systemic sclerosis.

Hudson M, Impens A, Baron M, Seibold JR, Thombs BD, Walker JG; Canadian Scleroderma Research Group, Steele R.

J Rheumatol. 2010 Nov;37(11):2307-12. doi: 10.3899/jrheum.100354. Epub 2010 Sep 15.

PMID:
20843907
38.

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.

Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, Wigley FM, Black CM, Fessler BJ, Merkel PA, Pope JE, Sweiss NJ, Doyle MK, Hellmich B, Medsger TA Jr, Morganti A, Kramer F, Korn JH, Seibold JR.

Ann Rheum Dis. 2011 Jan;70(1):32-8. doi: 10.1136/ard.2010.130658. Epub 2010 Aug 30.

39.

Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials.

Khanna D, Brown KK, Clements PJ, Elashoff R, Furst DE, Goldin J, Seibold JR, Silver RM, Tashkin DP, Wells AU.

Clin Exp Rheumatol. 2010 Mar-Apr;28(2 Suppl 58):S55-62. Epub 2010 Jun 24. Review.

PMID:
20576216
40.

Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis.

Huscher D, Pittrow D, Distler O, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Kowal-Bielecka O, Avouac J, Behrens F, Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE; EPOSS-OMERACT Group.

Clin Exp Rheumatol. 2010 Mar-Apr;28(2 Suppl 58):S47-52. Epub 2010 Jun 10.

PMID:
20576214
41.

Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design.

Khanna D, Seibold JR, Wells A, Distler O, Allanore Y, Denton C, Furst DE.

Curr Rheumatol Rev. 2010 May 1;6(2):138-144.

42.

Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.

Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira PE, Bancel DF, Allanore Y, Müller-Ladner U, Distler O, Iannone F, Pellerito R, Pileckyte M, Miniati I, Ananieva L, Gurman AB, Damjanov N, Mueller A, Valentini G, Riemekasten G, Tikly M, Hummers L, Henriques MJ, Caramaschi P, Scheja A, Rozman B, Ton E, Kumánovics G, Coleiro B, Feierl E, Szucs G, Von Mühlen CA, Riccieri V, Novak S, Chizzolini C, Kotulska A, Denton C, Coelho PC, Kötter I, Simsek I, de la Pena Lefebvre PG, Hachulla E, Seibold JR, Rednic S, Stork J, Morovic-Vergles J, Walker UA.

Ann Rheum Dis. 2010 Oct;69(10):1809-15. doi: 10.1136/ard.2009.114264. Epub 2010 Jun 15.

43.

Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis.

Seibold JR, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells A, Matucci Cerinic M, Riemekasten G, Emery P, Chadha-Boreham H, Charef P, Roux S, Black CM.

Arthritis Rheum. 2010 Jul;62(7):2101-8. doi: 10.1002/art.27466. Erratum in: Arthritis Rheum. 2010 Oct;62(10):3005.

44.

Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group.

Avouac J, Kowal-Bielecka O, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Distler O, Furst DE; EPOSS Group.

Ann Rheum Dis. 2010 Jul;69(7):1360-3. doi: 10.1136/ard.2009.120303. Epub 2010 May 14. Review.

45.

Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group.

Kowal-Bielecka O, Avouac J, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE, Distler O; EPOSS Group.

J Rheumatol. 2010 Jan;37(1):105-15. doi: 10.3899/jrheum.090661. Epub 2009 Dec 1.

46.

Sexual activity and functioning in female scleroderma patients.

Impens AJ, Rothman J, Schiopu E, Cole JC, Dang J, Gendrano N, Rosen RC, Seibold JR.

Clin Exp Rheumatol. 2009 May-Jun;27(3 Suppl 54):38-43.

PMID:
19796560
47.

A world of progress in systemic sclerosis.

Clements PJ, Matucci-Cerinic M, Bombardieri S, Seibold JR.

Clin Exp Rheumatol. 2009 May-Jun;27(3 Suppl 54):1. No abstract available.

PMID:
19796552
48.

Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).

Khanna D, Distler O, Avouac J, Behrens F, Clements PJ, Denton C, Foeldvari I, Giannini E, Huscher D, Kowal-Bielecka O, Lovell D, Matucci-Cerinic M, Mayes M, Merkel PA, Nash P, Opitz CF, Pittrow D, Rubin L, Seibold JR, Steen V, Strand CV, Tugwell PS, Varga J, Zink A, Furst DE; CRISS; EPOSS.

J Rheumatol. 2009 Oct;36(10):2356-61. doi: 10.3899/jrheum.090372.

49.

Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis.

Schiopu E, Hsu VM, Impens AJ, Rothman JA, McCloskey DA, Wilson JE, Phillips K, Seibold JR.

J Rheumatol. 2009 Oct;36(10):2264-8. doi: 10.3899/jrheum.090270. Epub 2009 Sep 15.

PMID:
19755613
50.

Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.

Khanna D, Hays RD, Maranian P, Seibold JR, Impens A, Mayes MD, Clements PJ, Getzug T, Fathi N, Bechtel A, Furst DE.

Arthritis Rheum. 2009 Sep 15;61(9):1257-63. doi: 10.1002/art.24730.

Supplemental Content

Loading ...
Support Center